32 recruiting, 24 completed, 16 active not recruiting, 13 unknown. 117 Phase 2, 19 Phase 1, 10 Phase 3.
Follow Neoplasm, Residual: new trials by email Literature Review of Neoplasm, Residual trials Research Report on Neoplasm, Residual
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate INCA33890 in the Treatment of Circulating Tumor DNA-Positive Stage II/III Microsatellite Stable Colorectal Cancer After Curative Resection and Chemotherapy INCA33890 - CRC (Colorectal Cancer) | Phase 2 | Recruiting | Incyte Corporation | 40 | 2026-12-14 | 2026-11-17 |
| MRD-Adapted Low-Dose Radiation Therapy During Frontline Chemoimmunotherapy for Diffuse Large B-Cell Lymphoma Low-Dose Radiation Therapy (LDRT), Standard Frontline Chemoimmunotherapy - Diffuse Large B-Cell Lymphoma | Phase 2 | Not yet recruiting | University of Nebraska | 50 | 2026-12-12 | 2026-11-06 |
| A Pragmatic Clinical Trial to Prevent Relapse for Myeloid Malignancies With Measurable Disease Prior to Allogeneic Transplant Maintenance Therapy, No intervention - Myeloid Disorders, Myelodysplastic Syndromes | Phase 2 | Not yet recruiting | Medical College of Wisconsin | 450 | 2026-12-01 | 2026-10-13 |
| Befotertinib Plus Chemotherapy With an MRD-guided Adaptive Strategy for Treatment Escalation and Response Optimization in EGFR-mutated NSCLC Patients Befotinib, Pemetrexed + Cisplatin /Carboplatin - Advanced Non-small Cell Lung Cancer (NSCLC), EGFR Exon 19 Deletion Mutation | Phase 2 | Recruiting | Guangzhou University of Traditional Chinese Medicine | 124 | 2026-11-30 | 2026-11-04 |
| Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer Montanide (Registered Trademark) ISA-51 VG Adjuvant, H1299 Cell Lysates, N-803 - Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma | Phase 1 / Phase 2 | Suspended | National Cancer Institute (NCI) | 30 | 2026-11-24 | 2026-11-19 |
| MRD and Imaging Guided Adaptive Neoadjuvant Therapy for Resectable NSCLC PD-1 inhibitor, Carboplatin, Nab-paclitaxel - Non-Small Cell Lung Cancer (NSCLC) | Phase 2 | Not yet recruiting | Peking University People's Hospital | 100 | 2026-11-01 | 2026-10-21 |
| Elranatamab With Mezigdomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma Dexamethasone, Mezigdomide, Elranatamab - Multiple Myeloma Refractory, Multiple Myeloma in Relapse | Phase 2 | Not yet recruiting | PETHEMA Foundation | 60 | 2026-11-01 | 2026-10-28 |
| CM336 Plus Daratumumab and Lenalidomide in Transplant-Ineligible Newly Diagnosed Multiple Myeloma CM336 (BCMA/CD3 bispecific antibody), Daratumumab, Lenalidomide - Multiple Myeloma | Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 24 | 2026-10-15 | 2026-10-26 |
| Comparing Lower Versus Standard Doses of Belantamab Mafodotin With Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma. Belantamab Mafodotin, Pomalidomide, Dexamethasone - Relapsed / Refractory Multiple Myeloma | Phase 2 | Not yet recruiting | Polish Myeloma Consortium | 228 | 2026-10-01 | 2026-08-06 |
| Nemtabrutinib With Venetoclax and Obinutuzumab in Patients With Chronic Lymphocytic Leukemia Nemtabrutinib, Venetoclax, Obinutuzumab - Chronic Lymphocytic Leukemia | Phase 2 | Not yet recruiting | Medical College of Wisconsin | 30 | 2026-10-01 | 2026-07-08 |
| SHR-A1811 Versus Trastuzumab Plus Pertuzumab in ctDNA-Positive HER2-Positive Early Breast Cancer After Pathologic Complete Response SHR-A1811, Trastuzumab, Pertuzumab - HER2-positive Breast Cancer, Early Breast Cancer (EBC) | Phase 2 | Not yet recruiting | Fudan University | 358 | 2026-10-01 | 2026-10-02 |
| Perioperative Adebrelimab for Locally Advanced Cervical Cancer Adebrelimab, Paclitaxel, Cisplatin - Locally Advanced Cervical Cancer | Phase 2 | Not yet recruiting | Anhui Provincial Hospital | 35 | 2026-10-01 | 2026-09-10 |
| ctDNA-Guided Immunotherapy for dMMR/MSI-H Colon Cancer PD-1 inhibitor, CTLA-4 inhibitor, ctDNA/MRD testing - Colon Cancer, Deficient Mismatch Repair | Phase 2 | Recruiting | Fudan University | 23 | 2026-09-14 | 2026-09-25 |
| Homoharringtonine, Lisaftoclax, and Azacitidine for AML After Venetoclax-Based Therapy Failure Lisaftoclax (APG-2575), homoharringtonine, Azacitidine (AZA) - Acute Myeloid Leukemia (AML) | Phase 2 | Enrolling by invitation | Guangdong Second Provincial General Hospital | 73 | 2026-09-01 | 2026-09-10 |
| Motixafortide for MRD Sensitization in AML Motixafortide - Acute Myeloid Leukemia, Measurable Residual Disease | Phase 2 | Recruiting | Washington University School of Medicine | 10 | 2026-07-23 | 2026-07-24 |
| Chidamide Maintenance for MRD-Positive Double-Expressor DLBCL in First Complete Remission Chidamide - Diffuse Large B-Cell Lymphoma | Phase 2 | Recruiting | Rong Tao | 69 | 2026-06-16 | 2026-06-18 |
| VEN+IDAC vs IDAC in AML Ventoclax, Cytarabine - AML (Acute Myelogenous Leukemia) | Phase 2 / Phase 3 | Enrolling by invitation | Guangdong Second Provincial General Hospital | 232 | 2026-04-01 | 2026-04-17 |
| Integrating Allogeneic NK Cells in High-risk Advanced Stage III-IV Nasopharyngeal Cancer Patients Allogenic expanded Natural Killer Cells (AlloNK1) - Nasopharyngeal Carcinoma (NPC), Minimal Residual Disease | Phase 1 / Phase 2 | Not yet recruiting | Singapore General Hospital | 31 | 2026-04-01 | 2026-03-30 |
| ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive) Ivonescimab, Docetaxel, Standard Treatment group - Non Small Cell Lung Cancer, Immune Checkpoint Inhibitors (ICIs) | Phase 2 | Recruiting | Second Xiangya Hospital of Central South University | 70 | 2026-03-10 | 2026-03-09 |
| PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease Datopotamab deruxtecan, Circulating tumor DNA (ctDNA) testing - Breast Cancer, Residual Disease | Phase 2 | Recruiting | UNC Lineberger Comprehensive Cancer Center | 78 | 2026-02-26 | 2026-11-13 |
Showing 20 of 117. Sign in to see all of them.
Precursor Cell Lymphoblastic Leukemia-Lymphoma (22) · Leukemia, Myeloid, Acute (21) · Multiple Myeloma (11) · Breast Neoplasms (9) · Burkitt Lymphoma (9) · Recurrence (9) · Myelodysplastic Syndromes (7) · Carcinoma, Non-Small-Cell Lung (6) · Leukemia, Lymphocytic, Chronic, B-Cell (6) · Leukemia (5) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (5) · Triple Negative Breast Neoplasms (5) · Colonic Neoplasms (4) · Colorectal Neoplasms (4)
Neoplasms (117) · Neoplastic Processes (117) · Pathologic Processes (117) · Pathological Conditions, Signs and Symptoms (117) · Neoplasms by Histologic Type (80) · Hemic and Lymphatic Diseases (72) · Hematologic Diseases (62) · Immune System Diseases (51) · Immunoproliferative Disorders (50) · Lymphoproliferative Disorders (49) · Leukemia (47) · Lymphatic Diseases (40) · Neoplasms by Site (34) · Leukemia, Lymphoid (28) · Leukemia, Myeloid (26)
blinatumomab (12) · Cyclophosphamide (11) · Azacitidine (9) · Dexamethasone (8) · Lenalidomide (8) · venetoclax (8) · Cytarabine (7) · Rituximab (6) · Carboplatin (5) · daratumumab (5) · fludarabine (5) · fludarabine phosphate (4) · pembrolizumab (4) · Busulfan (3) · Immune Checkpoint Inhibitors (3)
Nanfang Hospital, Southern Medical University (7) · M.D. Anderson Cancer Center (6) · National Cancer Institute (NCI) (4) · Novartis Pharmaceuticals (4) · Goethe University (3) · Institute of Hematology & Blood Diseases Hospital, China (3) · Medical College of Wisconsin (3) · Peking University People's Hospital (3) · Amgen (2) · Amgen Research (Munich) GmbH (2) · Beijing 302 Hospital (2) · Fudan University (2) · Gruppo Italiano Malattie EMatologiche dell'Adulto (2) · Guangdong Second Provincial General Hospital (2) · Masonic Cancer Center, University of Minnesota (2)
United States (47) · China (28) · Germany (13) · Italy (10) · Spain (10) · France (7) · Canada (5) · Belgium (4) · Netherlands (4) · Poland (4) · United Kingdom (4) · Australia (3) · Austria (3) · Mexico (3) · Norway (3)
Qifa Liu (4) · David S Schrump, M.D. (2) · Nicola Goekbuget, MD (2) · Robert J Kreitman, M.D. (2) · Aaron Goldberg, MD, PhD (1) · Albert Oriol, PhD (1) · Alessandro Rambaldi (1) · Alfonso Quintas-Cardama, MD (1) · Amanda Olson (1) · Amer Zeidan (1) · Andrzej Jakubowiak (1)
PMID 19141862, PMID 26308596, PMID 27209293, PMID 29358182, PMID 32619115, PMID 41671463, PMID 14710949, PMID 16195338, PMID 20087581, PMID 20388201, PMID 20606084, PMID 21719599, PMID 22058217, PMID 22442346, PMID 22592608, PMID 22851565, PMID 2350571, PMID 24128322, PMID 25192414, PMID 25749825, PMID 25966987, PMID 25999452, PMID 26778538, PMID 27216216, PMID 27511158, PMID 27531679, PMID 27557302, PMID 27618682, PMID 27705267, PMID 27717585, PMID 27859027, PMID 27896689, PMID 27913532, PMID 28054442, PMID 28379796, PMID 28494052, PMID 28835441, PMID 29127588, PMID 29305553, PMID 29388200, PMID 29884853, PMID 30037340, PMID 30254079, PMID 30255106, PMID 30498492, PMID 30702598, PMID 30831554, PMID 31324600, PMID 31435023, PMID 31452197
2023 (4), 2017 (2), P30CA015704 (2), 2015 (1), 2018 (1), 2019 (1), 2025 (1), K12HL087165 (1), P30CA014599 (1), P30CA016672 (1), R01CA290013 (1), U10CA180820 (1)